Kate Kelland
Reuters
January 21, 2011
LONDON, Jan 21 (Reuters) – The European Medicines Agency (EMA) said on Friday it was starting a review of the safety of Sanofi-Aventis’s (SASY.PA) heart drug Multaq after two cases of liver failure in patients on the drug.
In a separate move, the EU drugs regulator also said it was recommending approval of Sanofi’s prostate cancer drug Jevtana.
Jevtana is already available in the United States and the French drugmaker said response to the drug there had exceeded its expectations. Recommendations by the agency’s Committee for Medicinal Products for Human Use (CHMP) are usually endorsed by the European Commission within a couple of months.
The Emergency Election Sale is now live! Get 30% to 60% off our most popular products today!